Over-expression of VEGF and MMP-9 in residual tumor cells of hepatocellular carcinoma after embolization with lipidol

Abstract

The expression and implication of vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) in residual hepatic tumor cells after lipiodol embolization were investigated. Two weeks after transplantation of VX2 tumor cells into the livers of rabbits, a xenograft model of the human hepatic neoplasm was successfully established. Forty rabbits were randomly divided into control group (n=20) and lipiodol group (n=20). For the control group, 1 mL normal saline was injected through the gastroduodenal artery, whereas 0.3 mL/kg lipiodol was applied for the lipiodol group. One week after embolization, the expression level of VEGF in the plasma was measured by using enzyme-linked immunosorbent assay (ELISA). A three-step immunohistochemical technique (ABC) was employed to detect the protein levels of VEGF and MMP-9 and the quantitative PCR for their mRNA levels was performed in the residual tumor cells. The VEGF in the plasma was significantly higher in the lipiodol group (1.42±0.29 ng/mL) than in the control group (1.12±0.21 ng/mL) (P<0.01). Moreover, the positive rate of VEGF protein in the residual tumor cells was significantly higher in the lipiodol group (62.13%±7.69%) than in the control group (53.16%±9.17%) (P<0.05). Similarly, the MMP-9 expression in the residual tumor cells was higher in the lipiodol group. The mRNA levels of VEGF (2.9313±2.4231) and MMP-9 (3.5721±1.6107) in the lipiodol group were significantly higher than those in the control group (1.5728±0.9453 and 1.7573±1.0641, respectively, P<0.05). Therefore, it was reasonable to speculate that the increased expression of VEGF and MMP-9 in residual hepatic tumor cells and tumor angiogenesis post-embolization would be responsible for the increased metastatic potentiality and invasiveness of these cells.

Keywords

vascular endothelial growth factor / matrix metalloproteinase-9 / embolization / residual hepatic tumor cells / metastasis

References

[1] SemelaD., HeimM.. Hepatocellular carcinoma. Ther Umsch, 2011, 68(4): 213-217

[2] TakavasuK., AriiS., IkaiI., et al.. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology, 2006, 131(2): 461-469

[3] SongM.J., ParkC.H., KimJ.D., et al.. Drug-eluting bead loaded with doxorubicin versus conventional lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol, 2011, 23(6): 521-527

[4] OkabeK., BeppuT., HaraokaK., et al.. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma. Anticancer Res, 2011, 31(9): 2983-2988

[5] SergioA., CristoforiC., CardinR., et al.. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol, 2008, 103(4): 914-921

[6] MareelM., ConstantinoS.. Ecosystems of invasion and metastasis in mammary morphogenesis and cancer. Int J Dev Biol, 2011, 55(7–9): 671-684

[7] WeisS.M., ChereshD.A.. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med, 2011, 17(11): 1359-1370

[8] ShenY.C., HsuC., ChengA.L.. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol, 2010, 45(8): 794-807

[9] ChenL., ShiY., JiangC.Y., et al.. Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. Int J Biol Markers, 2011, 26(2): 108-116

[10] SulluY., DemiragG.G., YildirimA., et al.. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. 2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast. Pathol Res Pract, 2011, 207(12): 747-753

[11] XiangZ.L., ZengZ.C., FanJ., et al.. Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res, 2011, 17(16): 5463-5472

[12] BauschD., PauschT., KraussT., et al.. Neutrophil granulocyte-derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma. Angiogenesis, 2011, 14(3): 235-243

[13] GuT., LiC.X., FengY., et al.. Trans-arterial gene therapy for hepatocellular carcinoma in a rabbit model. World J Gastroenterol, 2007, 13(14): 2113-2117

[14] KeS., DingX.M., KongJ., et al.. Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma. J Transl Med, 2010, 8: 73-83

[15] XuT., ChenX.P., LiD., et al.. Expression of EMMPRIN in rabbit VX2 liver tumor tissue and significance. Zhonghua Shiyan Waike Zazi (Chinese), 2007, 24(1): 37-39

[16] XuT., ChenX.P., GuoY.X., et al.. Expression of MT1-MMP and its significance in rabbit VX2 tumor tissues after transarterial embolization with hydroxyapatite nanoparticles. Zhonghua Waike Zazi (Chinese), 2008, 46(8): 606-609

[17] ByrneA.M., Bouchier-HayesD.J., HarmeyJ.H.. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med, 2005, 9(4): 777-794

[18] CarmelietP.. VEGF as a key mediator of angiogenesis in cancer. Oncology, 2005, 69(3): 4-10

[19] ChenY., JiangL., SheF., et al.. Vascular endothelial growth factor-C promotes the growth and invasion of gallbladder cancer via an autocrine mechanism. Mol Cell Biochem, 2010, 345(1–2): 77-89

[20] KolevY., UetakeH., IidaS., et al.. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol, 2007, 14(10): 2738-2747

[21] ZhuA.X., DudaD.G., SahaniD.V., et al.. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol, 2011, 8(5): 292-301

[22] HuangX., HuangS., ZhangF., et al.. Lentiviral-mediated Smad4 RNAi promotes SMMC-7721 cell migration by regulation of MMP-2, VEGF and MAPK signaling. Mol Med Report, 2010, 3(2): 295-299

[23] OrlichenkoL.S., RadiskyD.C.. Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis, 2008, 25(6): 593-600

[24] MorrisonC., ManciniS., CipolloneJ., et al.. Microarray and proteomic analysis of breast cancer cell and osteoblast co-cultures: role of osteoblast matrix metalloproteinase (MMP)-13 in bone metastasis. J Biol Chem, 2011, 286(39): 34 271-34 285

[25] GolubkovV.S., ChekanovA.V., SavinovA.Y., et al.. Membrane type-1 matrix metalloproteinase confers aneuploidy and tumorigenicity on mammary epithelial cells. Cancer Res, 2006, 66(21): 10 460-10 465

[26] HuF., WangC., GuoS., et al.. δEF1 promotes osteolytic metastasis of MDA-MB-231 breast cancer cells by regulating MMP-1 expression. Biochim Biophys Acta, 2011, 1809(3): 200-210

[27] ZhangW., YangH.C., WangQ., et al.. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res, 2011, 31(10): 3423-3428

[28] der JagtM.F., WobbesT., StrobbeL.J., et al.. Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol, 2010, 101(3): 259-269

[29] BendardafR., BuhmeidaA., HilskaM., et al.. MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest, 2010, 28(1): 38-43

[30] ChenJ.S., WangQ., FuX.H., et al.. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res, 2009, 39(2): 177-186

[31] SaharinenP., EklundL., PulkkiK., et al.. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med, 2011, 17(7): 347-362

[32] Van HinsberghV.W., EaglseM.A., QuaxP.H.. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol, 2006, 26(4): 716-728

[33] TsaiM.Y., YangR.C., WuH.T., et al.. Anti-angiogenic effect of Tanshinone IIA involves inhibition of matrix invasion and modification of MMP-2/TIMP-2 secretion in vascu lar endothelial cells. Cancer Lett, 2011, 310(2): 198-206

[34] KimC.H., LeeJ.H., WonJ.H., et al.. Mesenchymal stem cells improve wound healing in vivo via early activation of matrix metalloproteinase-9 and vascular endothelial growth factor. J Korean Med Sci, 2011, 26(6): 726-733

[35] OrtegaN., WangK., FerraraN., et al.. Complementary interplay between matrix metalloproteinase-9, vascular endothelial growth factor and osteoclast function drives endochondral bone formation. Dis Model Mech, 2010, 3(3–4): 224-235

[36] YangP., YuanW., HeJ., et al.. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol Res, 2009, 39(12): 1169-1177

[37] ManK., NgK.T., XuA., et al.. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling. Clin Cancer Res, 2010, 16(3): 967-977

[38] HouY.K., WangY., CongW.M., et al.. Expression of tumor metastasis-suppressor gene KiSS-1 and matrix metalloproteinase-9 in portal vein tumor thrombus of hepatocellular carcinoma. Ai Zheng, 2007, 26(6): 591-595

[39] ZhangQ., ChenX., ZhouJ., et al.. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther, 2006, 5(7): 808-814

[40] TakavasuK., AriiS., IkaiI., et al.. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology, 2006, 131(2): 461-469

[41] LiapiE., GeorgiadesC.C., HongK., et al.. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol, 2007, 10(1): 2-11

[42] WangB., XuH., GaoZ.Q., et al.. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol, 2008, 49(5): 523-529

[43] ShimJ.H., ParkJ.W., KimJ.H., et al.. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci, 2008, 99(10): 2037-2044

[44] RheeT.K., YoungJ.Y., LarsonA.C., et al.. Effect of transcatheter arterial embolization on levels of hypoxia-inducible factor-1alpha in rabbit VX2 liver tumors. J Vasc Interv Radiol, 2011, 18(5): 639-645

[45] DengG., ZhaoD.L., LiG.C., et al.. Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor. Cardiovasc Intervent Radiol, 2011, 34(4): 824-832

[46] JananiP., SivakumariK., GeethaA., et al.. Bacoside A downregulates matrix metalloproteinases 2 and 9 in DEN-induced hepatocellular carcinoma. Cell Biochem Funct, 2010, 28(2): 164-169

This project was supported by grants from the Natural Science Foundation of Shandong Province of China (No. Y2007C102), and the Medical Science and Technology Development Foundation of Shandong Province of China (No. 2007H2071).